Correlation Between Stille AB and Enorama Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Stille AB and Enorama Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Stille AB and Enorama Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Stille AB and Enorama Pharma AB, you can compare the effects of market volatilities on Stille AB and Enorama Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Stille AB with a short position of Enorama Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Stille AB and Enorama Pharma.

Diversification Opportunities for Stille AB and Enorama Pharma

0.52
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Stille and Enorama is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Stille AB and Enorama Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enorama Pharma AB and Stille AB is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Stille AB are associated (or correlated) with Enorama Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enorama Pharma AB has no effect on the direction of Stille AB i.e., Stille AB and Enorama Pharma go up and down completely randomly.

Pair Corralation between Stille AB and Enorama Pharma

Assuming the 90 days trading horizon Stille AB is expected to under-perform the Enorama Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Stille AB is 3.32 times less risky than Enorama Pharma. The stock trades about -0.21 of its potential returns per unit of risk. The Enorama Pharma AB is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  394.00  in Enorama Pharma AB on August 26, 2024 and sell it today you would lose (17.00) from holding Enorama Pharma AB or give up 4.31% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Stille AB  vs.  Enorama Pharma AB

 Performance 
       Timeline  
Stille AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Stille AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Enorama Pharma AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Stille AB and Enorama Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Stille AB and Enorama Pharma

The main advantage of trading using opposite Stille AB and Enorama Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Stille AB position performs unexpectedly, Enorama Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enorama Pharma will offset losses from the drop in Enorama Pharma's long position.
The idea behind Stille AB and Enorama Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Complementary Tools

Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.